Repeated treatment with cannabidiol but not Δ9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance

Neuropharmacology

Volumn 52, Issue 4, 2007, Pages 1079-1087

  Hayakawa, Kazuhide ^a   Mishima, Kenichi ^a   Nozako, Masanori ^a   Ogata, Ayumi ^a   Hazekawa, Mai ^a   Liu, An Xin ^a   Fujioka, Masayuki ^a   Abe, Kohji ^b   Hasebe, Nobuyoshi ^b   Egashira, Nobuaki ^a   Iwasaki, Katsunori ^a   Fujiwara, Michihiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

9 Tetrahydrocannabinol; ( ) Cannabidiol; Cerebral ischemia; Neuroprotection; Tolerance

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; CANNABIDIOL; CANNABINOID 1 RECEPTOR; DRONABINOL; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; RIMONABANT; SEROTONIN 1A ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; DRUG TOLERANCE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TREATMENT DURATION;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; CANNABIDIOL; CEREBRAL INFARCTION; CEREBROVASCULAR CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG TOLERANCE; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE; NEUROPROTECTIVE AGENTS; PIPERAZINES; PIPERIDINES; PYRAZOLES; SEROTONIN ANTAGONISTS; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 33847261953     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.11.005     Document Type: Article

References (38)

1. Abood M.E., and Martin B.R. Neurobiology of marijuana abuse. Trends Pharmacol. Sci. 13 (1992) 201-206
2. Adnot S., Samoyeau R., and Weitzenblum E. Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil. Blood Press. Suppl. 3 (1995) 47-57
3. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Mo F.M., Liu J., and Kunos G. Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106 (2005) 133-145
4. Bonfils P.K., Reith J., Hasseldam H., and Johansen F.F. Estimation of the hypothermic component in neuroprotection provided by cannabinoids following cerebral ischemia. Neurochem. Int. 49 (2006) 508-518
5. Braida D., Pegorini S., Arcidiacono M.V., Consalez G.G., Croci L., and Sala M. Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci. Lett. 346 (2003) 61-64
6. Brand-Williams W., Cuvelier M.E., and Berset C. Use of a free radical method to evaluate antioxidant activity. Lebensm-Wiss. Technol. 28 (1995) 25-30
7. Carrier E.J., Auchampach J.A., and Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 7895-7900
8. David B., Gareth P., Wayne L.D., and Robin C.H. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 27 (2006) 1-4
9. Egashira N., Hayakawa K., Mishima K., Kimura H., Iwasaki K., and Fujiwara M. Neuroprotective effect of γ-glutamylethylamide (theanine) on cerebral infarction in mice. Neurosci. Lett. 363 (2004) 58-61
10. Forsyth K.D., and Levinsky R.J. Preparative procedures of cooling and re-warming increase leukocyte integrin expression and function on neutrophils. J. Immunol. Methods 128 (1990) 159-163
11. Hampson A.J., Grimaldi M., Lolic M., Wink D., Rosenthal R., and Axelrod J. Neuroprotective antioxidants from marijuana. Ann. N.Y. Acad. Sci. 899 (2000) 274-282
12. Hampson A.J., Grimaldi M., and Axelrod J. (-) Delta9-tetrahydrocannabinol are neuroprotective antioxidant. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 8268-8273
13. 1 cannabinoid receptor mechanism. Neuroreport 15 (2004) 2381-2385
14. Hill R.H., Svensson E., Dewael Y., and Grillner S. 5-HT inhibits N-type but not L-type Ca(2+) channels via 5-HT1A receptors in lamprey spinal neurons. Eur. J. Neurosci. 18 (2003) 2919-2924
15. Iuvone T., Esposito G., Esposito R., Santamaria R., Di Rosa M., and Izzo A.A. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J. Neurochem. 89 (2004) 134-141
16. Jin K.L., Mao X.O., Goldsmith P.C., and Greenberg D.A. CB1 cannabinoid receptor induction in experimental stroke. Ann. Neurol. 48 (2000) 257-261
17. Kanner J., Frankel E., Granit R., German B., and Kinsella J.E. Natural antioxidants in grapes and wines. J. Agric. Food Chem. 42 (1994) 64-69
18. Kaplan B.L., Rockwell C.E., and Kaminski N.E. Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. J. Pharmacol. Exp. Ther. 306 (2003) 1077-1085
19. Kurabayashi H., Kubota K., Take H., Tamura K., and Shirakura T. Effects of hyporthermal stress on the ultrastructure of platelets with reference to the localization of platelet peroxidase and fibrinogen in vivo. Am. J. Hematol. 56 (1997) 244-247
20. Leker R.R., Gai N., Mechoulam R., and Ovadia H. Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 34 (2003) 2000-2006
21. Mathew R.J., Wilson W.H., Chiu N.Y., Turkington T.G., Degrado T.R., and Coleman R.E. Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr. Scand. 100 (1999) 67-75
22. Mathew R.J., Wilson W.H., Chiu N.Y., Turkington T.G., Degrado T.R., Coleman R.E., and Provenzale J. Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography. Psychiatr. Res. 116 (2002) 173-185
23. Mechoulam R., Parker L.A., and Gallily R. Cannabidiol: an overview of some pharmacological aspects. J. Clin. Pharmacol. 42 (2002) 11S-19S
24. Mishima K., Egashira N., Hirosawa N., Fuji M., Matsumoto Y., Iwasaki K., and Fujiwara M. Characteristics of learning and memory impairment induced by Δ9-tetrahydrocannabinol in rats. Jpn. J. Pharmacol. 87 (2001) 297-308
25. 1A receptor-dependent mechanism. Stroke 36 (2005) 1071-1076
26. Renyi L., Moller K.A., Ensler K., and Evenden J. The non-competitive NMDA receptor antagonist (+)MK801 counteracts the long-lasting attenuation of the hypothermic response induced by acute doses of 8-OH-DPAT in the rat. Neuropharmacology 31 (1992) 1265-1268
27. Rubino T., Vigano D., Massi P., and Parolaro D. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940. J. Neurochem. 75 (2000) 2080-2086
28. Russo E.B., Burnett A., Hall B., and Parker K.K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 3010 (2005) 37-43
29. Semkova I., Wolz P., and Krieglstein J. Neuroprotective effect of 5-HT1A receptor agonist, Bay X3702, demonstrated in vitro and in vivo. Eur. J. Pharmacol. 359 (1998) 251-260
30. Sim L.J., Hamson R.E., Deadwyler S.A., and Childers S.R. Effects of chronic treatment with D9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgS autoradiography in rat brain. J. Neurosci. 1 (1996) 8057-8066
31. Sim-Selly L.J., and Martin B.R. Effect of chronic administration of R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta (9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J. Pharmacol. Exp. Ther. 303 (2002) 36-44
32. Son S., and Lewis B.A. Free radical scavenging and antioxidative activity of caffeic acid amide and ester analogues: structure activity relationship. J. Agric. Food Chem. 50 (2002) 468-472
33. Watanabe K., Narimatsu S., Yamamoto I., and Yoshimura H. Difference in tolerance development of hypothermia and pentobarbital-induced sleep prolongating effect of 11-hydroxy-delta 8-detrahydrocannabinol and 11-oxo-delta 8-tetrahydrocannabinol in mice. Eur. J. Pharmacol. 77 (1982) 53-56
34. Watanabe K., Narimatsu S., Yamamoto I., and Yoshimura H. Development of tolerance and cross-tolerance to the cataleptogenic effects of delta 8-tetrahydrocannabinol and 11-hydroxy-delta 8-tetrahydrocannabinol in mice. Eur. J. Pharmacol. 94 (1983) 349-351
35. Watzl B., Scuderi P., and Watson R.R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int. J. Immunopharmacol. 13 (1991) 1091-1097
36. Wiley J.L., and Martin B.R. Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem. Phys. Lipids 121 (2002) 57-63
37. Young A.H., McShane R., Park S.B., and Cowen P.J. Buspirone-induced hypothermia in normal male volunteers. Biol. Psychiatr. 34 (1993) 665-666
38. Yoshida T., Mori K., Hatano T., Okumura T., Uehara I., Komagoe K., Fujita Y., and Okuda T. Studies on inhibition mechanism of autoxidation by tannins and flavonoids. Chem. Pharm. Bull. 37 (1989) 1919-1921